Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SX 682

Next Previous
Drug Profile

SX 682

Alternative Names: SX-682

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntrix Biosystems
  • Developer Boehringer Ingelheim; Bristol-Myers Squibb; National Cancer Institute (USA); Syntrix Biosystems; University of Rochester; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Benzene derivatives; Boronic acids; Ethers; Fluorinated hydrocarbons; Fluorobenzenes; Pyrimidines; Small molecules
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Prostate cancer
  • Phase I/II Colorectal cancer; Malignant melanoma; Myelodysplastic syndromes
  • No development reported Pancreatic cancer

Most Recent Events

  • 28 Apr 2025 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Hormone refractory, Combination therapy, Second-line therapy or greater) in Switzerland (PO) (NCT07002320)
  • 28 Apr 2025 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Hormone refractory, Combination therapy, Second-line therapy or greater) in United Kingdom (PO) (NCT07002320)
  • 01 Oct 2024 Roswell Park Cancer Institute plans to initiate a phase I trial for Multiple Myeloma (In combination therapy, Second-line therapy or greater) (PO) (NCT06622005)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top